Key result
Protease inhibitors show no independent association with QTc prolongation in HIV patients.
Why the study?
Protease inhibitors are suspected to contribute to QTc interval prolongation and torsades de pointes in HIV-infected patients, but many factors can prolong QTc interval.
Are protease inhibitors associated with QTc interval prolongation in HIV-infected patients?
Population
978 unselected HIV-infected patients
Comparison
HIV-infected patients treated with protease inhibitors vs those not treated with protease inhibitors
Design
Prospective single-centre cross-sectional study
Authors
Loading...
QTc prolongation in HIV patients is not independently linked to PIs; challenges prior in vitro concerns and leaves open roles for infection duration and comorbidities.
Cross-Sectional (n=978)
No
Are protease inhibitors associated with QTc interval prolongation in HIV-infected patients?
p-value: p=0.99
Protease inhibitors are not independently associated with QTc prolongation in HIV patients; rather, QTc prolongation is related to traditional risk factors and the duration of HIV infection.
Charbit et al. (2008) conducted a cross-sectional in HIV infection (n=978). Protease inhibitors (PIs) vs. No protease inhibitors was evaluated on QTc interval prolongation (p=0.99). In HIV-infected patients, protease inhibitor use was not independently associated with QTc interval prolongation (P=0.99), which was instead related to common causes and duration of HIV infection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: